Laus personal page - To The Moon

Laus

Laus

No personal profile

86Follow

1Followers

0Topic

0Badge

2021-06-04

Nice nice

Forget Alibaba, These 3 Chinese Tech Stocks Are Better Buys

2021-06-08

Can invest?

FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades

2021-07-06

Nice oh

2021-06-28

To the moon

2021-06-25

To the moon

2021-06-24

To the moon

2021-06-23

Nio to the moon

2021-06-21

To the moon

2021-06-20

To the moon

2021-06-19

nice stock

2021-06-18

To the moon

2021-06-17

To the moon

2021-06-14

To the moon

2021-06-13

To the moon

2021-06-12

to the moon

2021-06-11

To the moon

2021-06-10

To the moon

2021-06-09

Nice stock

2021-06-08

To the moon

2021-06-07

To the moon

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3573725658355720","uuid":"3573725658355720","gmtCreate":1610631761862,"gmtModify":1622514234620,"name":"Laus","pinyin":"laus","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":86,"tweetSize":25,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.12","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.74%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.19%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":157859788,"gmtCreate":1625578698644,"gmtModify":1703744180905,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"Nice oh","listText":"Nice oh","text":"Nice oh","images":[{"img":"https://static.tigerbbs.com/c0259840bf51470689a75801c86946b6","width":"750","height":"2140"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157859788","isVote":1,"tweetType":1,"viewCount":301,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150126393,"gmtCreate":1624890351612,"gmtModify":1703847230895,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/8f472443680ad9bc43981c6cab774847","width":"750","height":"2260"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150126393","isVote":1,"tweetType":1,"viewCount":196,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":122737956,"gmtCreate":1624632847075,"gmtModify":1703842354896,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/c08733ed246a5107d2f569f072c6e21e","width":"750","height":"2320"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/122737956","isVote":1,"tweetType":1,"viewCount":379,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":128702922,"gmtCreate":1624530183666,"gmtModify":1703839487279,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/f305493efc604f7c2527b3a8b7c581c2","width":"750","height":"2450"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/128702922","isVote":1,"tweetType":1,"viewCount":333,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":121030428,"gmtCreate":1624443081964,"gmtModify":1703836824410,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"Nio to the moon","listText":"Nio to the moon","text":"Nio to the moon","images":[{"img":"https://static.tigerbbs.com/8afb94fc4ccf6c5a93506595eab46441","width":"750","height":"2330"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121030428","isVote":1,"tweetType":1,"viewCount":501,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":167872356,"gmtCreate":1624262649775,"gmtModify":1703831853038,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/062d8ac6a2980438a5efd9b1f0811a6f","width":"750","height":"2260"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167872356","isVote":1,"tweetType":1,"viewCount":241,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":164145055,"gmtCreate":1624185548577,"gmtModify":1703830317750,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/3f31ff6e37a9d31b981052f5a28d9aa5","width":"750","height":"2210"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/164145055","isVote":1,"tweetType":1,"viewCount":319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":165999211,"gmtCreate":1624084727433,"gmtModify":1703828571390,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"nice stock","listText":"nice stock","text":"nice stock","images":[{"img":"https://static.tigerbbs.com/549124109d9a8a7ae36bc2255180719e","width":"750","height":"2270"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/165999211","isVote":1,"tweetType":1,"viewCount":329,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":166586000,"gmtCreate":1624017868200,"gmtModify":1703826653609,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/4eb0dc302823079d0e71e5e7e1484b17","width":"750","height":"2390"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166586000","isVote":1,"tweetType":1,"viewCount":281,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":161308673,"gmtCreate":1623903419692,"gmtModify":1703823114134,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/33369fde86d5271204205ad76141f7cf","width":"750","height":"2330"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161308673","isVote":1,"tweetType":1,"viewCount":459,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":184943847,"gmtCreate":1623682090789,"gmtModify":1704208628329,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/564324b693a800bf16e93d868eb558d2","width":"750","height":"2140"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/184943847","isVote":1,"tweetType":1,"viewCount":168,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":182904733,"gmtCreate":1623549673522,"gmtModify":1704205817282,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/e3739d2f75b4bf31f856c7a87da71a51","width":"750","height":"2210"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182904733","isVote":1,"tweetType":1,"viewCount":126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":186161625,"gmtCreate":1623478824367,"gmtModify":1704204797891,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"to the moon","listText":"to the moon","text":"to the moon","images":[{"img":"https://static.tigerbbs.com/ccf20a12a04c016bd858b936f3f1c196","width":"750","height":"2270"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/186161625","isVote":1,"tweetType":1,"viewCount":197,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":181224934,"gmtCreate":1623397807528,"gmtModify":1704202510043,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/e4af9bae6e4d486e3bfde0ec1f4841a1","width":"750","height":"2450"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181224934","isVote":1,"tweetType":1,"viewCount":74,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":183173083,"gmtCreate":1623317756842,"gmtModify":1704200756313,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/cf48be373a93b4876f295b0c941645dd","width":"750","height":"2330"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183173083","isVote":1,"tweetType":1,"viewCount":149,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":180108166,"gmtCreate":1623193285355,"gmtModify":1704197872880,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"Nice stock","listText":"Nice stock","text":"Nice stock","images":[{"img":"https://static.tigerbbs.com/866c12412f95cfcd5ff25124e654f1f7","width":"750","height":"2270"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180108166","isVote":1,"tweetType":1,"viewCount":150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":114743649,"gmtCreate":1623107966481,"gmtModify":1704196047394,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"Can invest?","listText":"Can invest?","text":"Can invest?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/114743649","repostId":"1108033863","repostType":4,"repost":{"id":"1108033863","kind":"news","pubTimestamp":1623087360,"share":"https://ttm.financial/m/news/1108033863?lang=&edition=fundamental","pubTime":"2021-06-08 01:36","market":"us","language":"en","title":"FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades","url":"https://stock-news.laohu8.com/highlight/detail?id=1108033863","media":"cnbc","summary":"(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer","content":"<div>\n<p>(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 01:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1108033863","content_text":"(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer's and the first new medicine for the disease in nearly two decades.The FDA's decision was highly anticipated. The drug, which is marketed under the name Aduhelm, is also expected to generate billions of dollars in revenue for the company.\"We are well-aware of the attention surrounding this approval,\" Dr. Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, said in a press release. \"We understand that Aduhelm has garnered the attention of the press, the Alzheimer's patient community, our elected officials, and other interested stakeholders.\"\"With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review,\" Cavazzoni added.Alzheimer’s disease is a progressive neurodegenerative disorder that slowly destroys memory and thinking skills. More than 6 million Americans are living with the disease, according toestimates by the Alzheimer’s Association.By 2050, that number is projected to rise to nearly 13 million, according to the group.There were previously no drugs cleared by the FDA that can slow the mental decline from Alzheimer’s, which is the sixth leading cause of death in the United States. The U.S. agency has approved Alzheimer’s drugs aimed at helping symptoms, not actually slowing the disease itself.Federal regulators have faced intense pressure from friends and family members of Alzheimer’s patients asking to fast-track aducanumab, but the road to regulatory approval has been a controversial one since it showed promise in 2016.In March of 2019, Biogen pulled work on the drug after an analysis from an independent group revealed it was unlikely to work. The company then shocked investors several months later by announcing it would seek regulatory approval for the drug after all.Shares of Biogen soared in Novemberafter it won backing from FDA staff, who said the company showed highly “persuasive” evidence aducanumab was effective and that it had “an acceptable safety profile that would support use in individuals with Alzheimer’s disease.”But two days later, a panel of outside experts that advises theU.S. agency unexpectedly declined to endorsethe experimental drug, citing unconvincing data. It also criticized agency staff for what it called an overly positive review.When Biogen sought approval for the drug in late 2019, its scientists said a new analysis of a larger data set showed that aducanumab “reduced clinical decline in patients with early Alzheimer’s disease.”Alzheimer’s experts and Wall Street analysts were immediately skeptical, with some wondering whether the clinical trial data was enough to prove that the drug works and whether approval could make it harder for other companies to enroll patients in their own drug trials.Some doctorshave said they won’t prescribethe drug if it does reach the market, because of the mixed data package supporting the company’s application.Supporters, including advocacy groups and family members of those living with the disease desperate for a new treatment, have acknowledged that the data isn’t perfect. However, they argue that it could help some patients with Alzheimer’s, a progressive and debilitating disease.Biogen’s drug targets a “sticky” compound in the brain known as beta-amyloid, which scientists expect plays a role in the devastating disease. The company has previously estimated about 1.5 million people with early Alzheimer’s in the U.S. could be candidates for the drug, according to Reuters.The FDA decision is expected to reverberate throughout the biopharma sector, RBC Capital Markets analyst Brian Abrahams said in a note to clients on June 1.The U.S. agency said Monday it determined there was “substantial evidence” the drug helps patients.“As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease,” it said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":113,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114749609,"gmtCreate":1623107926901,"gmtModify":1704196045911,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/242e3477145babd662ce89fb87513eba","width":"750","height":"2510"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114749609","isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":114932779,"gmtCreate":1623041376291,"gmtModify":1704194871926,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/3dbefb85065ff99ab7725ec7511b87df","width":"750","height":"2210"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114932779","isVote":1,"tweetType":1,"viewCount":153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":112624262,"gmtCreate":1622867621056,"gmtModify":1704192764137,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"Good stock at the moment","listText":"Good stock at the moment","text":"Good stock at the moment","images":[{"img":"https://static.tigerbbs.com/fbcc5db49ba6f38076695786c6cbcd1a","width":"750","height":"2210"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/112624262","isVote":1,"tweetType":1,"viewCount":107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":118470252,"gmtCreate":1622759680976,"gmtModify":1704190461121,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"Nice nice","listText":"Nice nice","text":"Nice nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/118470252","repostId":"2140422463","repostType":4,"repost":{"id":"2140422463","kind":"highlight","pubTimestamp":1622734323,"share":"https://ttm.financial/m/news/2140422463?lang=&edition=fundamental","pubTime":"2021-06-03 23:32","market":"us","language":"en","title":"Forget Alibaba, These 3 Chinese Tech Stocks Are Better Buys","url":"https://stock-news.laohu8.com/highlight/detail?id=2140422463","media":"Motley Fool","summary":"Don't underestimate JD and these two other e-commerce companies.","content":"<p><b>Alibaba</b> (NYSE:BABA), China's top e-commerce and cloud company, lost nearly 10% of its value from January to late May, underperforming many industry peers. An antitrust probe in China, tighter auditing standards in the U.S., and the rotation from growth to value stocks all weighed down its stock.</p>\n<p>Alibaba's stock might look cheap at 18 times forward earnings, but analysts still expect its earnings to dip 3% this year as it absorbs a record $2.75 billion antitrust fine. It will also need to halt its exclusive deals with big brands, which could soften its defenses against smaller e-commerce marketplaces.</p>\n<p>And that's not all. Alibaba could be forced to divest its media assets and share its user data with the government, while its fintech affiliate, Ant Group, will be more tightly regulated as a financial holding company.&nbsp;Alibaba might weather all these headwinds and recover over the long term, but its stock could remain dead money for the foreseeable future.</p>\n<p>Instead of betting on Alibaba's potential comeback, investors should consider buying shares of Chinese tech stocks that aren't in regulatory crosshairs. These three e-commerce companies fit the bill: <b>JD.com </b>(NASDAQ:JD), <b>Pinduoduo</b> (NASDAQ:PDD), and <b>Baozun</b> (NASDAQ:BZUN).</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F628813%2Fgettyimages-1170687091.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"393\"><span>Image source: Getty Images.</span></p>\n<h2>1. JD.com</h2>\n<p>JD.com is China's second-largest e-commerce company after Alibaba. However, it's actually the country's largest direct retailer, since it generates most of its revenue from its first-party marketplace.</p>\n<p>Unlike Alibaba, which generates most of its e-commerce revenue from third-party sellers on Taobao and Tmall, JD takes on its own inventories and fulfills orders with its logistics network. This business model is more capital-intensive, but it shields its buyers from fake products.</p>\n<p>Alibaba's co-founder, Jack Ma, once said JD's lower-margin business model would end in a \"tragedy,\" but economies of scale gradually kicked in and enabled it to generate consistent profits. JD's logistics arm also balanced out its costs by offering its services to third-party customers.</p>\n<p>JD's revenue and&nbsp;adjusted earnings rose 29% and 57%, respectively, in 2020. It ended the first quarter with nearly 500 million annual active consumers, and analysts expect its revenue and earnings to grow another 26% and 13%, respectively, this year.</p>\n<p>JD doesn't face as much regulatory heat as Alibaba, it margins are expanding, and the stock trades at just 28 times forward earnings estimates and less than 1 times estimated sales.</p>\n<h2>2. Pinduoduo</h2>\n<p>Pinduoduo is the third-largest e-commerce player in China in terms of annual revenue, but in terms of total shoppers, it's actually bigger than JD, with 628 million annual active buyers. Like Alibaba, Pinduoduo generates most of its revenue through listing fees and ads for third-party merchants.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/864f7f52e87d48721cc5ea7d15e3b4b0\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<p>Pinduoduo carved out a niche with its discount marketplace, which encouraged shoppers to team up for group discounts. That strategy, which relied heavily on users sharing links across social networks, caught on across China's lower-tier cities.</p>\n<p>Pinduoduo subsequently expanded into China's top-tier cities and partnered with bigger brands to challenge Alibaba and JD. It also gained an early mover's advantage in online agriculture by enabling over 12 million farmers to directly ship their produce to customers.</p>\n<p>Pinduoduo's revenue surged 97% in&nbsp;2020, then soared another 239% year-over-year in the first quarter of 2021. Analysts expect its revenue to grow 92% for the full year. Those estimates are impressive for a stock that trades at about eight times this year's sales.</p>\n<p>Pinduoduo is still unprofitable due to its aggressive discounts, subsidies for sellers, and the expansion of its logistics network. However, its adjusted operating and net losses still narrowed year-over-year last quarter, and it could gradually inch toward profitability as it increases its scale.</p>\n<h2>3. Baozun</h2>\n<p>Baozun is sometimes called the \"<b>Shopify</b> of China\", but that comparison is misleading. Unlike Shopify, which provides self-serve e-commerce services to smaller businesses, Baozun mainly provides end-to-end e-commerce solutions to large international companies.</p>\n<p>It can be difficult for large U.S. companies to build Chinese websites, launch marketing campaigns, and set up e-commerce marketplaces, so Baozun is a \"<a href=\"https://laohu8.com/S/AONE\">one</a>-stop shop\" that handles all those needs. It also helps companies integrate their online marketplaces with Tmall, JD, and Pinduoduo, which makes it a well-balanced play on China's booming e-commerce sector.</p>\n<p>Baozun's business model is capital-intensive, but it expanded its margins in recent years by pivoting from a \"distribution-based\" model, in which it directly fulfilled orders, to a \"non-distribution\" based model, which allows its clients to directly ship their products to their customers.</p>\n<p>Baozun's revenue and adjusted earnings increased 22% and 50%, respectively, in 2020. Ninety-two percent of its GMV (gross merchandise volume) came from its non-distribution-based business. Analysts expect its revenue and adjusted earnings to rise 35% and 5%, respectively, this year.</p>\n<p>This oft-overlooked stock trades at just 19 times forward earnings and 1.5 times this year's sales, which might make it an undervalued growth stock if investors fall in love with Chinese tech companies again.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forget Alibaba, These 3 Chinese Tech Stocks Are Better Buys</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForget Alibaba, These 3 Chinese Tech Stocks Are Better Buys\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 23:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/03/forget-alibaba-these-3-chinese-tech-stocks-are-bet/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alibaba (NYSE:BABA), China's top e-commerce and cloud company, lost nearly 10% of its value from January to late May, underperforming many industry peers. An antitrust probe in China, tighter auditing...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/03/forget-alibaba-these-3-chinese-tech-stocks-are-bet/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴","JD":"京东","BZUN":"宝尊电商","PDD":"拼多多"},"source_url":"https://www.fool.com/investing/2021/06/03/forget-alibaba-these-3-chinese-tech-stocks-are-bet/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140422463","content_text":"Alibaba (NYSE:BABA), China's top e-commerce and cloud company, lost nearly 10% of its value from January to late May, underperforming many industry peers. An antitrust probe in China, tighter auditing standards in the U.S., and the rotation from growth to value stocks all weighed down its stock.\nAlibaba's stock might look cheap at 18 times forward earnings, but analysts still expect its earnings to dip 3% this year as it absorbs a record $2.75 billion antitrust fine. It will also need to halt its exclusive deals with big brands, which could soften its defenses against smaller e-commerce marketplaces.\nAnd that's not all. Alibaba could be forced to divest its media assets and share its user data with the government, while its fintech affiliate, Ant Group, will be more tightly regulated as a financial holding company. Alibaba might weather all these headwinds and recover over the long term, but its stock could remain dead money for the foreseeable future.\nInstead of betting on Alibaba's potential comeback, investors should consider buying shares of Chinese tech stocks that aren't in regulatory crosshairs. These three e-commerce companies fit the bill: JD.com (NASDAQ:JD), Pinduoduo (NASDAQ:PDD), and Baozun (NASDAQ:BZUN).\nImage source: Getty Images.\n1. JD.com\nJD.com is China's second-largest e-commerce company after Alibaba. However, it's actually the country's largest direct retailer, since it generates most of its revenue from its first-party marketplace.\nUnlike Alibaba, which generates most of its e-commerce revenue from third-party sellers on Taobao and Tmall, JD takes on its own inventories and fulfills orders with its logistics network. This business model is more capital-intensive, but it shields its buyers from fake products.\nAlibaba's co-founder, Jack Ma, once said JD's lower-margin business model would end in a \"tragedy,\" but economies of scale gradually kicked in and enabled it to generate consistent profits. JD's logistics arm also balanced out its costs by offering its services to third-party customers.\nJD's revenue and adjusted earnings rose 29% and 57%, respectively, in 2020. It ended the first quarter with nearly 500 million annual active consumers, and analysts expect its revenue and earnings to grow another 26% and 13%, respectively, this year.\nJD doesn't face as much regulatory heat as Alibaba, it margins are expanding, and the stock trades at just 28 times forward earnings estimates and less than 1 times estimated sales.\n2. Pinduoduo\nPinduoduo is the third-largest e-commerce player in China in terms of annual revenue, but in terms of total shoppers, it's actually bigger than JD, with 628 million annual active buyers. Like Alibaba, Pinduoduo generates most of its revenue through listing fees and ads for third-party merchants.\nImage source: Getty Images.\nPinduoduo carved out a niche with its discount marketplace, which encouraged shoppers to team up for group discounts. That strategy, which relied heavily on users sharing links across social networks, caught on across China's lower-tier cities.\nPinduoduo subsequently expanded into China's top-tier cities and partnered with bigger brands to challenge Alibaba and JD. It also gained an early mover's advantage in online agriculture by enabling over 12 million farmers to directly ship their produce to customers.\nPinduoduo's revenue surged 97% in 2020, then soared another 239% year-over-year in the first quarter of 2021. Analysts expect its revenue to grow 92% for the full year. Those estimates are impressive for a stock that trades at about eight times this year's sales.\nPinduoduo is still unprofitable due to its aggressive discounts, subsidies for sellers, and the expansion of its logistics network. However, its adjusted operating and net losses still narrowed year-over-year last quarter, and it could gradually inch toward profitability as it increases its scale.\n3. Baozun\nBaozun is sometimes called the \"Shopify of China\", but that comparison is misleading. Unlike Shopify, which provides self-serve e-commerce services to smaller businesses, Baozun mainly provides end-to-end e-commerce solutions to large international companies.\nIt can be difficult for large U.S. companies to build Chinese websites, launch marketing campaigns, and set up e-commerce marketplaces, so Baozun is a \"one-stop shop\" that handles all those needs. It also helps companies integrate their online marketplaces with Tmall, JD, and Pinduoduo, which makes it a well-balanced play on China's booming e-commerce sector.\nBaozun's business model is capital-intensive, but it expanded its margins in recent years by pivoting from a \"distribution-based\" model, in which it directly fulfilled orders, to a \"non-distribution\" based model, which allows its clients to directly ship their products to their customers.\nBaozun's revenue and adjusted earnings increased 22% and 50%, respectively, in 2020. Ninety-two percent of its GMV (gross merchandise volume) came from its non-distribution-based business. Analysts expect its revenue and adjusted earnings to rise 35% and 5%, respectively, this year.\nThis oft-overlooked stock trades at just 19 times forward earnings and 1.5 times this year's sales, which might make it an undervalued growth stock if investors fall in love with Chinese tech companies again.","news_type":1},"isVote":1,"tweetType":1,"viewCount":99,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3582029020196512","authorId":"3582029020196512","name":"Ottaman","avatar":"https://community-static.tradeup.com/news/dd18af68811ccb7e2c80b842b185f1af","crmLevel":6,"crmLevelSwitch":0,"idStr":"3582029020196512","authorIdStr":"3582029020196512"},"content":"pls reply","text":"pls reply","html":"pls reply"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114743649,"gmtCreate":1623107966481,"gmtModify":1704196047394,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"Can invest?","listText":"Can invest?","text":"Can invest?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/114743649","repostId":"1108033863","repostType":4,"repost":{"id":"1108033863","kind":"news","pubTimestamp":1623087360,"share":"https://ttm.financial/m/news/1108033863?lang=&edition=fundamental","pubTime":"2021-06-08 01:36","market":"us","language":"en","title":"FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades","url":"https://stock-news.laohu8.com/highlight/detail?id=1108033863","media":"cnbc","summary":"(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer","content":"<div>\n<p>(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 01:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1108033863","content_text":"(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer's and the first new medicine for the disease in nearly two decades.The FDA's decision was highly anticipated. The drug, which is marketed under the name Aduhelm, is also expected to generate billions of dollars in revenue for the company.\"We are well-aware of the attention surrounding this approval,\" Dr. Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, said in a press release. \"We understand that Aduhelm has garnered the attention of the press, the Alzheimer's patient community, our elected officials, and other interested stakeholders.\"\"With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review,\" Cavazzoni added.Alzheimer’s disease is a progressive neurodegenerative disorder that slowly destroys memory and thinking skills. More than 6 million Americans are living with the disease, according toestimates by the Alzheimer’s Association.By 2050, that number is projected to rise to nearly 13 million, according to the group.There were previously no drugs cleared by the FDA that can slow the mental decline from Alzheimer’s, which is the sixth leading cause of death in the United States. The U.S. agency has approved Alzheimer’s drugs aimed at helping symptoms, not actually slowing the disease itself.Federal regulators have faced intense pressure from friends and family members of Alzheimer’s patients asking to fast-track aducanumab, but the road to regulatory approval has been a controversial one since it showed promise in 2016.In March of 2019, Biogen pulled work on the drug after an analysis from an independent group revealed it was unlikely to work. The company then shocked investors several months later by announcing it would seek regulatory approval for the drug after all.Shares of Biogen soared in Novemberafter it won backing from FDA staff, who said the company showed highly “persuasive” evidence aducanumab was effective and that it had “an acceptable safety profile that would support use in individuals with Alzheimer’s disease.”But two days later, a panel of outside experts that advises theU.S. agency unexpectedly declined to endorsethe experimental drug, citing unconvincing data. It also criticized agency staff for what it called an overly positive review.When Biogen sought approval for the drug in late 2019, its scientists said a new analysis of a larger data set showed that aducanumab “reduced clinical decline in patients with early Alzheimer’s disease.”Alzheimer’s experts and Wall Street analysts were immediately skeptical, with some wondering whether the clinical trial data was enough to prove that the drug works and whether approval could make it harder for other companies to enroll patients in their own drug trials.Some doctorshave said they won’t prescribethe drug if it does reach the market, because of the mixed data package supporting the company’s application.Supporters, including advocacy groups and family members of those living with the disease desperate for a new treatment, have acknowledged that the data isn’t perfect. However, they argue that it could help some patients with Alzheimer’s, a progressive and debilitating disease.Biogen’s drug targets a “sticky” compound in the brain known as beta-amyloid, which scientists expect plays a role in the devastating disease. The company has previously estimated about 1.5 million people with early Alzheimer’s in the U.S. could be candidates for the drug, according to Reuters.The FDA decision is expected to reverberate throughout the biopharma sector, RBC Capital Markets analyst Brian Abrahams said in a note to clients on June 1.The U.S. agency said Monday it determined there was “substantial evidence” the drug helps patients.“As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease,” it said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":113,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":157859788,"gmtCreate":1625578698644,"gmtModify":1703744180905,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"Nice oh","listText":"Nice oh","text":"Nice oh","images":[{"img":"https://static.tigerbbs.com/c0259840bf51470689a75801c86946b6","width":"750","height":"2140"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157859788","isVote":1,"tweetType":1,"viewCount":301,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150126393,"gmtCreate":1624890351612,"gmtModify":1703847230895,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/8f472443680ad9bc43981c6cab774847","width":"750","height":"2260"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150126393","isVote":1,"tweetType":1,"viewCount":196,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":122737956,"gmtCreate":1624632847075,"gmtModify":1703842354896,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/c08733ed246a5107d2f569f072c6e21e","width":"750","height":"2320"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/122737956","isVote":1,"tweetType":1,"viewCount":379,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":128702922,"gmtCreate":1624530183666,"gmtModify":1703839487279,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/f305493efc604f7c2527b3a8b7c581c2","width":"750","height":"2450"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/128702922","isVote":1,"tweetType":1,"viewCount":333,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":121030428,"gmtCreate":1624443081964,"gmtModify":1703836824410,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"Nio to the moon","listText":"Nio to the moon","text":"Nio to the moon","images":[{"img":"https://static.tigerbbs.com/8afb94fc4ccf6c5a93506595eab46441","width":"750","height":"2330"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121030428","isVote":1,"tweetType":1,"viewCount":501,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":167872356,"gmtCreate":1624262649775,"gmtModify":1703831853038,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/062d8ac6a2980438a5efd9b1f0811a6f","width":"750","height":"2260"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167872356","isVote":1,"tweetType":1,"viewCount":241,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":164145055,"gmtCreate":1624185548577,"gmtModify":1703830317750,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/3f31ff6e37a9d31b981052f5a28d9aa5","width":"750","height":"2210"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/164145055","isVote":1,"tweetType":1,"viewCount":319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":165999211,"gmtCreate":1624084727433,"gmtModify":1703828571390,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"nice stock","listText":"nice stock","text":"nice stock","images":[{"img":"https://static.tigerbbs.com/549124109d9a8a7ae36bc2255180719e","width":"750","height":"2270"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/165999211","isVote":1,"tweetType":1,"viewCount":329,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":166586000,"gmtCreate":1624017868200,"gmtModify":1703826653609,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/4eb0dc302823079d0e71e5e7e1484b17","width":"750","height":"2390"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166586000","isVote":1,"tweetType":1,"viewCount":281,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":161308673,"gmtCreate":1623903419692,"gmtModify":1703823114134,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/33369fde86d5271204205ad76141f7cf","width":"750","height":"2330"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161308673","isVote":1,"tweetType":1,"viewCount":459,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":184943847,"gmtCreate":1623682090789,"gmtModify":1704208628329,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/564324b693a800bf16e93d868eb558d2","width":"750","height":"2140"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/184943847","isVote":1,"tweetType":1,"viewCount":168,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":182904733,"gmtCreate":1623549673522,"gmtModify":1704205817282,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/e3739d2f75b4bf31f856c7a87da71a51","width":"750","height":"2210"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182904733","isVote":1,"tweetType":1,"viewCount":126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":186161625,"gmtCreate":1623478824367,"gmtModify":1704204797891,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"to the moon","listText":"to the moon","text":"to the moon","images":[{"img":"https://static.tigerbbs.com/ccf20a12a04c016bd858b936f3f1c196","width":"750","height":"2270"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/186161625","isVote":1,"tweetType":1,"viewCount":197,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":181224934,"gmtCreate":1623397807528,"gmtModify":1704202510043,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/e4af9bae6e4d486e3bfde0ec1f4841a1","width":"750","height":"2450"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181224934","isVote":1,"tweetType":1,"viewCount":74,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":183173083,"gmtCreate":1623317756842,"gmtModify":1704200756313,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/cf48be373a93b4876f295b0c941645dd","width":"750","height":"2330"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183173083","isVote":1,"tweetType":1,"viewCount":149,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":180108166,"gmtCreate":1623193285355,"gmtModify":1704197872880,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"Nice stock","listText":"Nice stock","text":"Nice stock","images":[{"img":"https://static.tigerbbs.com/866c12412f95cfcd5ff25124e654f1f7","width":"750","height":"2270"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180108166","isVote":1,"tweetType":1,"viewCount":150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":114749609,"gmtCreate":1623107926901,"gmtModify":1704196045911,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/242e3477145babd662ce89fb87513eba","width":"750","height":"2510"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114749609","isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":114932779,"gmtCreate":1623041376291,"gmtModify":1704194871926,"author":{"id":"3573725658355720","authorId":"3573725658355720","name":"Laus","avatar":"https://static.tigerbbs.com/378271708d4733ee22a03d619150e6f2","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573725658355720","authorIdStr":"3573725658355720"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[{"img":"https://static.tigerbbs.com/3dbefb85065ff99ab7725ec7511b87df","width":"750","height":"2210"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114932779","isVote":1,"tweetType":1,"viewCount":153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}